Search academic texts

Information × Registration Number 0223U002437, 0122U002452 , R & D reports Title To develop radionuclide and cytological determinants for evaluating the effectiveness of targeted therapy of iodine-negative metastases of differentiated thyroid cancer popup.stage_title Head Solodiannykova Oksana I., д.мед.н. Registration Date 21-02-2023 Organization National Cancer Institute popup.description2  The object of the study is 28 patients with iodine-negative metastases of differentiated thyroid cancer. The purpose of the work is to develop a method of treatment of iodine-negative metastases of differentiated thyroid cancer with the help of tyrosine kinase inhibitors and to determine the significance of radionuclide determinants in the assessment of effectiveness. Research methods and equipment – scintigraphy of the whole body with 99mTc-MIBI; whole body scintigraphy with 99mTc-DMCA; positron emission tomography with 18F-FDG; methods of statistical processing of results; two-detector gamma camera of the company "Mediso" (Hungary), single-photon emission computed tomography (SPECT) "E. CAM 180”. 28 patients with differentiated thyroid cancer were examined, 10 of them, treated with the targeted drug sorafenib, underwent SVT with 99mTc-MIBI in order to assess the therapeutic effectiveness by scintigraphic imaging. A method of treatment with drugs, tyrosine kinase inhibitors, of iodine-negative metastases of DSCLC has been developed. In 10 patients with differentiated thyroid cancer and iodine-negative metastases, a scintigraphic evaluation of the effectiveness of treatment using PET with 18F-FDG was performed. In 8 patients, in whom bone damage was detected, treatment was carried out with the help of radionuclide and remote radiation therapy. Control of treatment effectiveness was carried out using SVT with 99mTc-MDR. Product Description popup.authors Danylenko Viktoriia V. Dzhuzha Dmytro O. Sukach Georgii H. popup.nrat_date 2023-02-21 Close